Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to $946.6 million.

  • ImmunityBio's Shares Outstanding (Weighted Average) rose 3602.64% to $946.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $946.6 million, marking a year-over-year increase of 3602.64%. This contributed to the annual value of $697.3 million for FY2024, which is 3709.45% up from last year.
  • As of Q3 2025, ImmunityBio's Shares Outstanding (Weighted Average) stood at $946.6 million, which was up 3602.64% from $888.2 million recorded in Q2 2025.
  • Over the past 5 years, ImmunityBio's Shares Outstanding (Weighted Average) peaked at $946.6 million during Q3 2025, and registered a low of $382.7 million during Q1 2021.
  • Its 5-year average for Shares Outstanding (Weighted Average) is $550.4 million, with a median of $437.5 million in 2023.
  • As far as peak fluctuations go, ImmunityBio's Shares Outstanding (Weighted Average) soared by 209.42% in 2022, and later skyrocketed by 5706.35% in 2024.
  • ImmunityBio's Shares Outstanding (Weighted Average) (Quarter) stood at $389.2 million in 2021, then grew by 2.74% to $399.9 million in 2022, then rose by 27.19% to $508.6 million in 2023, then soared by 37.09% to $697.3 million in 2024, then skyrocketed by 35.75% to $946.6 million in 2025.
  • Its last three reported values are $946.6 million in Q3 2025, $888.2 million for Q2 2025, and $853.2 million during Q1 2025.